Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bicycle Therapeutics closes £20mm Series A

Executive Summary

Bicycle Therapeutics Ltd. (developing peptide drugs) raised £20mm ($32mm) in Series A funding from returning shareholders Atlas Venture, Novartis Venture Fund, SR One, SV Life Sciences, and Astellas Venture Management. The proceeds will support ongoing development of bicycle drug conjugates (BDCs) for oncology indications. It hopes to bring two compounds to clinical proof-of-concept by 2017 and up to four more BDCs to preclinical proof-of-concept.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies